CD33 and neoplasm: The addition of LV increased the viable population of activated CAR T cells (70% vs 12% viable, 10 μM MTX ± LV) and the CD33-expressing tumor cell line MV4-11 (65% vs 11% viable, 10 μM MTX ± LV) (Supplementary Fig. 8).